TX-FLUENCE
9.5.2022 14:02:07 CEST | Business Wire | Press release
Fluence , a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced its sponsorship of Wageningen University & Research’s (WUR) third Autonomous Greenhouse Challenge in the Netherlands. For the first time in the challenge’s history, WUR leveraged a broad-spectrum LED-only lighting system—specifically Fluence’s VYPR 3p solution—instead of high-pressure sodium (HPS) fixtures. WUR also implemented Fluence’s innovative lighting control solution, Wireless Flex Dimming, into the facility.
Wageningen University & Research is dedicated to researching the future of agriculture by exploring autonomous greenhouse technology, climate control, crop modeling, advanced sensors, data intelligence, computer vision and robotics. Beginning in June 2021, WUR organized its third Autonomous Greenhouse Challenge to task different international teams with sustainably growing vegetables in a fully automated greenhouse environment.
“We expect that food production in greenhouse horticulture can be further improved by adding more artificial intelligence to the agricultural industry,” said Silke Hemming, who leads the scientific research team for greenhouse technology at WUR, in a statement . “We make connections with international partners through this unique challenge, so that we can take major steps.”
One of the challenges growers face when transitioning from HPS to LED luminaires is that a typical HPS system is limited in its dimming capabilities, unlike LED technology. By leveraging state-of-the-art, qualified Bluetooth mesh technology enabled by Technology Partner SILVAIR, Fluence’s Wireless Flex Dimming solution allows growers to have precise control of dim light levels. By connecting the VYPR top light fixtures to the climate computer through Wireless Flex Dimming, the participants were empowered to implement advanced lighting control strategies that maximized plant growth and quality.
“In any greenhouse or controlled environment, the reliability of a cultivation system is paramount,” said Theo Tekstra, Fluence’s technical director for Europe, Middle East and Africa. “Wireless Flex Dimming enables growers to simplify installation and gain solid wireless control of their light levels, whether in an autonomous scientific experiment or a large-scale greenhouse. We are now implementing this technology for customers with more than 7,000 connected fixtures.”
WUR’s Autonomous Greenhouse Challenge also seeks to discover how artificial intelligence can play a role in the future of cultivation, including how to reduce energy input and cost.
“The complete cultivation process is handled by AI and algorithms developed by the teams,” Tekstra added. “One important input factor is the strong fluctuations in high energy prices. Fluence’s Wireless Flex Dimming integration with the Ridder climate computer allows the teams to modulate the lights within their lighting strategy algorithms to optimize energy costs. Fluence’s mission is to help the world grow smarter—something these incredible teams are tackling head-on. We are delighted to support WUR and this initiative with our advanced lighting solutions.”
Fluence continues to demonstrate how secure, intelligent lighting solutions based on the latest technology innovations can add value to the global horticulture industry. The Wireless Flex Dimming Receiver has been awarded PSA Certified™ Level 1 (an independent measurement of security best practices spearheaded by Arm) from Riscure. PSA Certified is recognized by the DesignLights Consortium as an approved cybersecurity standard for networked lighting control systems.
Results from the challenge will be published in July 2022. To follow the competing teams’ progress, visit WUR’s greenhouse challenge dashboard here . For more information on Fluence and its portfolio of controls and luminaires, visit www.fluence.science .
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005233/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom